Sanofi-Aventis And Nichi-Iko Announce JV For Generics In Japan
This article was originally published in PharmAsia News
Executive Summary
Toyama-based Japanese generics drug maker Nichi-Iko announced May 28 that Sanofi-Aventis will invest $48 million in the company to jumpstart its generics business in Japan
You may also be interested in...
Daiichi Sankyo Adds To Japan's Biosimilar Fray In Two-compound Deal
Daiichi Sankyo is teaming with virtual startup Coherus BioSciences for etanercept and rituximab.
Top Japanese Pharmas Show Appetite For Emerging Market Expansion, Will Generics Follow?
TOKYO - Japanese pharma companies are trying to determine how to expand into new markets, ranging from the U.S. to China, and IMS Health data show a slow move away from dependence on the domestic market for Japan's leading companies
Top Japanese Pharmas Show Appetite For Emerging Market Expansion, Will Generics Follow?
TOKYO - Japanese pharma companies are trying to determine how to expand into new markets, ranging from the U.S. to China, and IMS Health data show a slow move away from dependence on the domestic market for Japan's leading companies